Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration

Abstract The metabolism and pharmacokinetics of fasiglifam (TAK-875, 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid), a selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist, were studied following intravenous (5 mg/kg) and oral administration (10 and 50 mg/kg) to male and female Sprague Dawley rats. Following intravenous dosing at 5 mg/kg, peak observed plasma concentrations of 8.8/9.2 µg/ml were seen in male and female rats respectively. Following oral dosing, peak plasma concentrations at 1 h of ca. 12.4/12.9 µg/ml for 10 mg/kg and 76.2/83.7 µg/ml for 50 mg/kg doses were obtained for male and female rats respectively. Drug concentrations then declined in the plasma of both sexes with t1/2’s of 12.4 (male) and 11.2 h (female). Oral bioavailability was estimated to be 85-120% in males and females at both dose levels. Urinary excretion was low, but in a significant sex-related difference, female rats eliminated ca. 10-fold more drug-related material by this route. Fasiglifam was the principal drug-related compound in plasma, with 15 metabolites, including the acyl glucuronide, also detected. In addition to previously identified metabolites, a novel biotransformation, that produced a side-chain shortened metabolite via elimination of CH2 from the acetyl side chain was noted with implications for drug toxicity.

[1]  I. Wilson,et al.  Acyl glucuronide reactivity in perspective. , 2020, Drug discovery today.

[2]  K. Richardson,et al.  A Cyclic Ion Mobility-Mass Spectrometry System. , 2019, Analytical chemistry.

[3]  Liping Pan,et al.  Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans , 2019, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  L. Benet,et al.  Characterization of Fasiglifam-Related Liver Toxicity in Dogs , 2019, Drug Metabolism and Disposition.

[5]  R. A. Thompson,et al.  The metabolic fate of fenclozic acid in chimeric mice with a humanized liver , 2018, Archives of Toxicology.

[6]  M. Player,et al.  Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  R. Wehr,et al.  The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice , 2017, Biochemical pharmacology.

[8]  M. Nakajima,et al.  Toxicological potential of acyl glucuronides and its assessment. , 2017, Drug metabolism and pharmacokinetics.

[9]  Andy Z. X. Zhu,et al.  Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  K. Kaku,et al.  Long‐term safety and efficacy of fasiglifam (TAK‐875), a G‐protein‐coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52‐week open‐label phase III study , 2016, Diabetes, obesity & metabolism.

[11]  Xiaoyan Chen,et al.  Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury , 2015, Drug Metabolism and Disposition.

[12]  K. Kaku,et al.  Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial , 2015, Diabetes, obesity & metabolism.

[13]  K. Kaku Fasiglifam as a new potential treatment option for patients with type 2 diabetes , 2013, Expert opinion on pharmacotherapy.

[14]  M. Darnell,et al.  Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism. , 2013, Chemical research in toxicology.

[15]  H. Naik,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers , 2012, Journal of clinical pharmacology.

[16]  Yan Li,et al.  In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.

[17]  I. Wilson,et al.  Diclofenac metabolism in the mouse: Novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Osamu Okazaki,et al.  Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide , 2010, Drug Metabolism and Disposition.

[19]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[20]  I. Wilson,et al.  Integrated HPLC-MS and 1H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  M. Hartshorn,et al.  Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters. , 2009, Rapid communications in mass spectrometry : RCM.

[22]  Y. Teffera,et al.  A Novel Bioactivation Pathway for 2-[2-(2,6-Dichlorophenyl)aminophenyl]ethanoic Acid (Diclofenac) Initiated by Cytochrome P450-Mediated Oxidative Decarboxylation , 2008, Drug Metabolism and Disposition.

[23]  Michael Gertz,et al.  Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data , 2008, Drug Metabolism and Disposition.